Citations

Clear

16281 citation(s) found for "Yu, David".

E-164 Safety profile of surgical embolectomy in acute ischemic stroke patients: a systematic review and meta-analysis
Pakkam, Madona , Bilgin, Cem , Kadirvel, R, Kallmes, D, Orscelik, Atakan , Musmar, Basel , Senol, Y, Ghozy, Sherief , Kadirvel, Ramanathan , Kallmes, David F.

Mayo Clinic

SNIS 21st annual meeting electronic poster abstracts | July 22, 2024 | Volume: No volume available | Issue: No issue available | Pages: A183.2-A184

10.1136/jnis-2024-snis.269 Get It

Pipeline versus non-pipeline flow diverter treatment for M1 aneurysms: A systematic review and meta-analysis
Şenol, Yiğit Can , Orscelik, Atakan , Bilgin, Cem , Kallmes, David F. , Kadirvel, Ramanathan , Arul, Santhosh , Orscelik, Atakan , Senol, Yigit Can , Kobeissi, Hassan , Ghozy, Sherief

Mayo Clinic

The Neuroradiology Journal | July 21, 2024 | Volume: 38 | Issue: 2 | Pages: 133-141

10.1177/19714009241260805 | PMID 39033417 Get It

Background The flow diversion treatment of aneurysms located distal to the Circle of Willis has recently increased in frequency. We conducted a systematic review and meta-analysis of the clinical and radiological outcomes of flow diverter (FD) embolization in treating M1 aneurysms. Methods PubMed, Web of Science, Ovid Medline, Ovid Embase, and Scopus were searched up to May 2024 using the Nested Knowledge platform. We included studies assessing the long-term clinical and radiological outcomes for M1 aneurysms. Results of FDs classified as Pipeline Embolization Devices (PED) versus other types of FDs. Angiographic occlusion rates, ischemic and hemorrhagic complications, and favorable clinic outcomes were included. All data were analyzed using R software version 4.2.2. Results Thirteen studies with 112 total patients (58 patients for PED and 54 patients for other FD devices) were included in our meta-analysis. The overall adequate (complete + near-complete) occlusion rates were 85.1%. The complete occlusion rate was higher with PED than with other FD devices (72.9% PED and 41.6% for non-PED FDs, respectively, p -value <.01). The ischemic complications were 9.9% and 9.0% for the PED and non-PED groups, respectively ( p -value = .89). The overall modified Rankin Scale 0–2 was 100% for the non-PED and 97.1% for the PED group ( p -value = .51). In-stent stenosis rate was 7.5% for PED devices compared to 2.6% in the non-PED group ( p -value = .35). Conclusions This relatively small meta-analysis showed high rates of adequate and complete occlusion in FD treatment of M1 segment aneurysms, with favorable safety profiles. PEDs were associated with higher rates of complete aneurysm occlusion compared to other types of FDs.
Treatment of lichen sclerosus with hydroxychloroquine: a Mayo Clinic experience
Akpala, Christeebella O. , Tekin, Burak , Torgerson, Rochelle R. , Wetter, David A. , Nguyen, Giang Huong , Akpala, Christeebella O , Nguyen, Giang H

Mayo Clinic

International Journal of Dermatology | July 20, 2024 | Volume: 63 | Issue: 10 | Pages: No page available

10.1111/ijd.17394 | PMID 39032011 Get It

AbstractBackgroundThere is a dearth of studies investigating the efficacy of hydroxychloroquine in the treatment of either anogenital lichen sclerosus or extragenital lichen sclerosus, a condition that, if left untreated, could lead to a greater degree of scarring and malignant transformation.ObjectiveThis study aims to analyze the demographic characteristics, clinicopathological features, treatment response, and outcomes of patients diagnosed with either anogenital or extragenital lichen sclerosus who received hydroxychloroquine therapy.MethodsA retrospective analysis was conducted involving 70 patients diagnosed with lichen sclerosus who underwent treatment with hydroxychloroquine at our institution between 2018 and 2023.ResultsAmong the cohort, 67 patients were female, and 3 were male. Extragenital lichen sclerosus was diagnosed in 23 patients, with 16 exhibiting concomitant morphea overlap. Itching was the predominant clinical presentation (67%). A notable proportion of patients (36%) had a connective tissue disorder, prompting hydroxychloroquine therapy. Among the 30 patients treated solely for lichen sclerosus, 21 demonstrated response and 9 had no response. From a broader comparison of response to hydroxychloroquine, the overall anogenital response rate was 84.6% as opposed to 50% in extragenital lichen sclerosus. The median time to initial response was 4 months. Adverse effects, predominantly mild, were observed in 10 (14.3%) patients.LimitationThis study is constrained by its retrospective nature and reliance on data from a single center, resulting in a limited sample size.ConclusionHydroxychloroquine demonstrates promise as a therapeutic option for anogenital lichen sclerosus because of its favorable response rates and low incidence of adverse effects. However, further investigations, including larger‐scale or prospective studies, are imperative to ascertain its definitive efficacy.
Advancements in APOE and dementia research: Highlights from the 2023 AAIC Advancements: APOE conference
Kloske, Courtney M. , Blue, Elizabeth , Carrillo, María C. , Chen, Xiaoying , Chiba‐Falek, Ornit , Davis, Albert A. , Paolo, Gilbert Di , Garretti, Francesca , Golden, Lesley R. , Heinecke, Jay W. , Herz, Joachim, Huang, Yadong , Kanekiyo, Takahisa , Khvorova, Anastasia, Hertog, Sascha J. Koppes‐den, Lamb, Bruce T. , Lawler, Paige E. , Litvinchuk, Alexandra , Liu, Chia‐Chen , Michaelson, D. M., Miller, Justin J. , Morganti, Josh M. , Oosthoek, Marlies , Ramachandran, Kapil V. , Ramakrishnan, Abhirami , Robert, Aiko, Sexton, Claire E. , Shah, Nilomi, Shue, Francis , Strickland, Michael R. , TCW, Julia , Thierry, Manon, Tuckey, Ryan A. , Ulrich, Jason D. , Wang, Na , Weninger, Stacie, Zhao, Na , Goate, Alison , Liu, Chia-Chen , Shue, Francis , Zhao, Na , Goate, Alison M , Belloy, Michaël E. , Bowman, Gregory R. , Gate, David M , Iadecola, Costantino , Johnson, Lance A. , Karch, Celeste M. , Khvorova, Anastasia , Hertog, Sascha Koppes-den , Le Guen, Yann , Mahinrad, Simin , Marcora, Edoardo , Mariño, Claudia , Narayan, Priyanka , Naslavsky, Michel Satya , Raulin, Ana‐Caroline , Saleh, Rasha N.M. , Sible, Isabel J. , Soranno, Andrea , Tsai, Li‐Huei , Kant, Rik van der , Wellington, Cheryl L. , Yassine, Hussein N. , Bu, Guojun , Holtzman, David M.

Mayo Clinic

Alzheimer's & Dementia | July 19, 2024 | Volume: 20 | Issue: 9 | Pages: 6590-6605

10.1002/alz.13877 | PMID 39031528 Get It

AbstractINTRODUCTIONThe apolipoprotein E gene (APOE) is an established central player in the pathogenesis of Alzheimer's disease (AD), with distinct apoE isoforms exerting diverse effects. apoE influences not only amyloid‐beta and tau pathologies but also lipid and energy metabolism, neuroinflammation, cerebral vascular health, and sex‐dependent disease manifestations. Furthermore, ancestral background may significantly impact the link between APOE and AD, underscoring the need for more inclusive research.METHODSIn 2023, the Alzheimer's Association convened multidisciplinary researchers at the “AAIC Advancements: APOE” conference to discuss various topics, including apoE isoforms and their roles in AD pathogenesis, progress in apoE‐targeted therapeutic strategies, updates on disease models and interventions that modulate apoE expression and function.RESULTSThis manuscript presents highlights from the conference and provides an overview of opportunities for further research in the field.DISCUSSIONUnderstanding apoE's multifaceted roles in AD pathogenesis will help develop targeted interventions for AD and advance the field of AD precision medicine.Highlights APOE is a central player in the pathogenesis of Alzheimer's disease. APOE exerts a numerous effects throughout the brain on amyloid‐beta, tau, and other pathways. The AAIC Advancements: APOE conference encouraged discussions and collaborations on understanding the role of APOE.
Optimizing cutpoints for clinical interpretation of brain amyloid status using plasma p‐tau217 immunoassays
Griswold, Michael , Bornhorst, Joshua A. , Graff‐Radford, Jonathan , Lowe, Val J. , Jack, Clifford R. , Petersen, Ronald , Algeciras‐Schimnich, Alicia , Algeciras-Schimnich, Alicia , Figdore, Daniel J. , Jack, Clifford R , Bornhorst, Joshua , Ramanan, Vijay K. , Vemuri, Prashanthi , Knopman, David S.

Mayo Clinic

Alzheimer's & Dementia | July 19, 2024 | Volume: 20 | Issue: 9 | Pages: 6506-6516

10.1002/alz.14140 | PMID 39030981 Get It

Abstract INTRODUCTION We aimed to evaluate clinical interpretation cutpoints for two plasma phosphorylated tau (p‐tau)217 assays (ALZpath and Lumipulse) as predictors of amyloid status for implementation in clinical practice. METHODS Clinical performance of plasma p‐tau217 against amyloid positron emission tomography status was evaluated in participants with mild cognitive impairment or mild dementia ( n = 427). RESULTS Using a one‐cutpoint approach (negative/positive), neither assay achieved ≥ 90% in both sensitivity and specificity. A two‐cutpoint approach yielding 92% sensitivity and 96% specificity provided the desired balance of false positives and false negatives, while categorizing 20% and 39% of results as indeterminate for the Lumipulse and ALZpath assays, respectively. DISCUSSION This study provides a systematic framework for selection of assay‐specific cutpoints for clinical use of plasma p‐tau217 for determination of amyloid status. Our findings suggest that a two‐cutpoint approach may have advantages in optimizing diagnostic accuracy while minimizing potential harm from false positive results. Highlights Phosphorylated tau (p‐tau)217 cutpoints for detection of amyloid pathology were established. A two‐cutpoint approach exhibited the best performance for clinical laboratory use. p‐tau217 assays differed in the percentage of results categorized as intermediate.
“Unkinking” the “Kink” Normalizes the Doppler Pattern
Blickenstaff, Elaina A. , O’Shea, Michael , Barry, Timothy , Arsanjani, Reza , Fasolino, John P., Hagler, Donald J. , Marcotte, François , Majdalany, David , Majdalany, David S , Hagler, Donald J , Arsanjani, Reza , Blickenstaff, Elaina A.

Mayo Clinic

Diagnostics | July 18, 2024 | Volume: 14 | Issue: 14 | Pages: 1550

10.3390/diagnostics14141550 | PMID 39061687 Get It

Coarctation of the aorta (CoA) comprises 5–7% of congenital heart disease and can present as an isolated narrowing in the aortic arch just distal to the left subclavian artery or can be associated with cardiac abnormalities such as a bicuspid aortic valve, aortopathy, or ventricular septal defects. With the advances in the medical field, intervention on CoA can either be via surgical repair or endovascular stenting. Echocardiography is the mainstay in diagnosing CoA, with tomographic imaging such as magnetic resonance imaging (MRI) or computed tomography providing supplementary assessment of the aorta, valves, and collateral vessels. We present a case of a young hypertensive male who was noted to have a continuous cardiac murmur with diagnostic Doppler pattern of CoA on echocardiography that normalized soon after percutaneous stenting.
The Liver Cirrhosis Network Cohort Study: Cirrhosis Definition, Study Population, and Endpoints
Tapper, Elliot B. , Goldberg, David S. , Parikh, Neehar D. , Welch, Nicole , Hameed, Bilal , Khalili, Mandana , Stolz, Andrew , Verna, Elizabeth C. , Brown, Robert S., VanWagner, Lisa B. , Moylan, Cynthia A. , Diehl, Anna Mae , Jones, Patricia D. , Shah, Vijay H. , Bajaj, Jasmohan S. , Group, for the LCN Study, Goldberg, David , Welch, Nicole , Khalili, Mandana , Stolz, Andrew , Sanyal, A J , VanWagner, Lisa B , Ladner, Daniela P , Moylan, Cynthia A , Jones, Patricia D , Loomba, Rohit , Simonetto, Douglas A , Bajaj, Jasmohan S , Parikh, Neehar D , Terrault, Norah A. , Sharpton, Suzanne R. , Brown, Robert S., Sanyal, Arun J. , Ladner, Daniela P. , Loomba, Rohit , Dasarathy, Srinivasan , Simonetto, Douglas A. , Group, for the LCN Study

Mayo Clinic

American Journal of Gastroenterology | July 17, 2024 | Volume: 120 | Issue: 3 | Pages: 570-575

10.14309/ajg.0000000000002953 | PMID 39018024 Get It

INTRODUCTION: One of the primary goals of the Liver Cirrhosis Network (LCN) is to develop a cohort study to better understand and predict the risk of hepatic decompensation and other clinical and patient-reported outcomes among patients with Child A cirrhosis. METHODS: The LCN consists of a Scientific Data Coordinating Center and 10 clinical centers whose investigators populate multiple committees. The LCN Definitions and Measurements Committee developed preliminary definitions of cirrhosis and its complications by literature review, expert opinion, and reviewing definition documents developed by other organizations. The Cohort Committee developed the study protocol with the input of the steering committee. RESULTS: The LCN developed a prospective cohort study to describe and predict the rates of incident clinical events pertaining to first decompensation and patient-reported outcomes. The LCN developed a pragmatic definition of compensated cirrhosis incorporating clinical, laboratory, imaging, and histological criteria. Definitions of incident and recompensated ascites, overt hepatic encephalopathy, variceal hemorrhage, bleeding because of portal gastropathy, and hepatocellular carcinoma were also codified. DISCUSSION: The LCN Cohort Study design will inform the natural history of cirrhosis in contemporary patients with compensated cirrhosis. The LCN Definitions and Measures Committee developed criteria for the definition of cirrhosis to standardize entry into this multicenter cohort study and standardized criteria for liver-related outcome measures. This effort has produced definitions intended to be both sensitive and specific as well as easily operationalized by study staff such that outcomes critical to the LCN cohort are identified and reported in an accurate and generalizable fashion. REGISTRATION: NCT05740358.
CAR-T cells for H3K27-altered diffuse midline gliomas: where do we stand?
Millesi, Elena , Rechberger, Julian S. , Power, Erica A , Rechberger, Julian S , Power, Erica A. , Daniels, David J.

Mayo Clinic

Immunotherapy | July 17, 2024 | Volume: 16 | Issue: 12 | Pages: 775-778

10.1080/1750743x.2024.2373043 | PMID 39016046 Get It

Use of corticosteroids for adult chronic pain interventions: sympathetic and peripheral nerve blocks, trigger point injections - guidelines from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, the Ameri
Benzon, Honorio T. , Elmofty, Dalia , Shankar, Hariharan , Rana, Maunak V., Shah, Shalini , Souza, Dmitri , Nagpal, Ameet , Abdi, Salahadin , Rafla, Christian , Eckmann, Maxim , Pino, Carlos A. , Rivera, Jessica , Schneider, Byron J. , Stout, Alison , Stengel, Angela D , Mina, Maged, FitzGerald, John , Hirsch, Joshua A , Manchikanti, Laxmaiah , Maus, Timothy P. , Chadwick, Andrea , Shah, Shalini , Nagpal, Ameet S , Abdi, Salahadin , Rafla, Christian , Doshi, Tina L , Hoang, Thanh D , Hunt, Christine , Pino, Carlos A , Schneider, Byron J , Stout, Alison , Stengel, Angela , FitzGerald, John D , Wasan, Ajay D , Provenzano, David Anthony , Narouze, Samer , Cohen, Steven P , Nelson, Ariana M , Shanthanna, Harsha , Benzon, Honorio T , Shankar, Hariharan , Abd-Elsayed, Alaa A , Doshi, Tina L , Rivera, Jessica, Wasan, Ajay D. , Provenzano, David , Narouze, Samer , Cohen, Steven P. , Nelson, Ariana M. , Shanthanna, Harsha

Mayo Clinic

Regional Anesthesia & Pain Medicine | July 16, 2024 | Volume: 51 | Issue: 6 | Pages: 642-659

10.1136/rapm-2024-105593 | PMID 39019502 Get It

Background There is potential for adverse events from corticosteroid injections, including increase in blood glucose, decrease in bone mineral density and suppression of the hypothalamic–pituitary axis. Published studies note that doses lower than those commonly injected provide similar benefit. Methods Development of the practice guideline was approved by the Board of Directors of American Society of Regional Anesthesia and Pain Medicine with several other societies agreeing to participate. The scope of guidelines was agreed on to include safety of the injection technique (landmark-guided, ultrasound or radiology-aided injections); effect of the addition of the corticosteroid on the efficacy of the injectate (local anesthetic or saline); and adverse events related to the injection. Based on preliminary discussions, it was decided to structure the topics into three separate guidelines as follows: (1) sympathetic, peripheral nerve blocks and trigger point injections; (2) joints; and (3) neuraxial, facet, sacroiliac joints and related topics (vaccine and anticoagulants). Experts were assigned topics to perform a comprehensive review of the literature and to draft statements and recommendations, which were refined and voted for consensus (≥75% agreement) using a modified Delphi process. The United States Preventive Services Task Force grading of evidence and strength of recommendation was followed. Results This guideline deals with the use and safety of corticosteroid injections for sympathetic, peripheral nerve blocks and trigger point injections for adult chronic pain conditions. All the statements and recommendations were approved by all participants after four rounds of discussion. The Practice Guidelines Committees and Board of Directors of the participating societies also approved all the statements and recommendations. The safety of some procedures, including stellate blocks, lower extremity peripheral nerve blocks and some sites of trigger point injections, is improved by imaging guidance. The addition of non-particulate corticosteroid to the local anesthetic is beneficial in cluster headaches but not in other types of headaches. Corticosteroid may provide additional benefit in transverse abdominal plane blocks and ilioinguinal/iliohypogastric nerve blocks in postherniorrhaphy pain but there is no evidence for pudendal nerve blocks. There is minimal benefit for the use of corticosteroids in trigger point injections. Conclusions In this practice guideline, we provided recommendations on the use of corticosteroids in sympathetic blocks, peripheral nerve blocks, and trigger point injections to assist clinicians in making informed decisions.